Rochester, NY 7/25/2009 10:12:43 AM
Hemispherx Biopharma, Inc. HEB, Hemispherx Biopharma Will Soon Provide Update On Global Pandemic Influenza Prevention
Hemispherx Biopharma, Inc
Recent reports show that Hemispherx Biopharma, will soon give updates on its Influenza research via teleconference. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States.
http://WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
There will be participation among Hemispherx's Medical Director, CEO, and the Managing Director of the Sage Group Investigational products and protocols to be discussed will include Hemispherx's Ampligen. FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
